-
The Belfer Center is part of Dana-Farber Cancer Institute. We advance discoveries and therapies to translate today’s science into tomorrow’s treatments.
-
We accelerate discovery and development of the next generation of targeted and immune-based therapies
-
We integrate academic and industrial research to drive clinical trials and improve patients’ lives
The Belfer Center is part of Dana-Farber Cancer Institute. We advance discoveries and therapies to translate today’s science into tomorrow’s treatments.
Spotlight
Twitter feed
The #ASCOBT23 program is now available! See which global thought leaders are joining us in Yokohama this August for a one-of-a-kind meeting exploring innovations in clinical cancer care.
Explore the program ➡️ https://t.co/HdyUjS5fMe @JSMO_official @lillian_siu
Presenting in the #AACR23 Exhibitor Spotlight Theater: Cellecta.
Monday, April 17, 3:00 PM; Theater A.
Learn more: https://t.co/PJgrQt70YW
How to Design a Successful Career Path in Cancer Research: In this #AACR23 career session (Sunday, April 16), early-career scientists will learn strategies to enhance the probability of success in the pursuit of their first independent research position. https://t.co/cHnfvHsxf7
The AACR is the Founding Organizer of the Rally for Medical Research, which marked its 10th anniversary in 2022 and brought more than 250 advocates to Washington, DC, to advocate for biomedical research. Learn more in the AACR Annual Impact Report:
https://t.co/xRqo3s65pM
The Winn CDA is a 2-year program offering training and resources to help early-stage investigators become independent clinical trial investigators with both community engagement and research skills. Register for the info session on March 28 to learn more: https://t.co/cwsVptWy1o
Draft guidance from @FDAOncology and a new federal law require trial sponsors to develop Diversity Action Plans to expand the representation of patient populations. An #AACR23 session on Monday, April 17 will highlight progress. https://t.co/OMT7KKGjQW
A New Era of Early-Stage Cancer Care: A Think Tank Discussion on the Clinical Impact of Pathologic Response to Immunotherapy—
This CME-accredited satellite symposium will take place at 6:30 PM on Saturday, April 15. Learn more: https://t.co/fGMw4SN0WA #AACR23
Presenting in the #AACR23 Exhibitor Spotlight Theater: NanoString Technologies.
Monday, April 17, 12:30 PM; Theater B.
Learn more: https://t.co/a3VrVSwSLG
Presenting in the #AACR23 Exhibitor Spotlight Theater: Cell Signaling Technology.
Monday, April 17, 3:00 PM; Theater B.
Learn more: https://t.co/xFOvXY93Zs
Find your next job at the Cancer and Biomedical Research Career Fair during the AACR Annual Meeting 2023, Saturday, April 15 in Orlando, FL. Submit your CV/resume to CancerCareers today and attend the fair for the chance to win great prizes.
https://t.co/EMfnRqAdJZ
#AACR23
Recent publications
Targeting TBK1 to overcome resistance to cancer immunotherapy.
Nature. 2023 Mar.
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.
N Engl J Med. 2023 Jan 5.
Announcements
We are proud of our alumni and we celebrate their successes! Read what Allison O’Connell and Kristin DePeaux say about their time at the Belfer.
Strategic alliances

Our strategic alliances drive research innovations and lead to improved therapies to benefit cancer patients
Donor highlight
Robert and Renée Belfer’s transformative cumulative Dana-Farber investment of more than $25 million launched the Robert A. and Renée E. Belfer Center for Applied Cancer Science. Their generosity enabled the Belfer Center to integrate its scientific teams, produce innovative cancer models, partner with industry leaders, and accelerate the development of revolutionary therapies to treat cancer. We are grateful for their vision and incredible support.
